Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ampicillin + gentamicin is a combination of two antibiotics used primarily for the treatment of severe bacterial infections, including neonatal and pediatric sepsis, endocarditis (especially due to Enterococcus species), and meningitis. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis. Gentamicin is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of the bacterial ribosome, inhibiting protein synthesis and causing misreading of mRNA. The combination exhibits synergistic bactericidal activity against certain organisms such as Enterococcus spp., Listeria monocytogenes, and some Gram-negative bacteria. This synergy makes it especially effective in serious infections where monotherapy may be insufficient[3][4][5]. Administration should be sequential rather than mixed in the same IV line or container due to chemical incompatibility[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ampicillin + gentamicin.